Cargando…
Protease Inhibitor Use in COVID-19
The outbreak of a large plaque, novel coronavirus pneumonia (NCP), which also named Coronavirus Disease 2019 (COVID-19) by the WHO, has detrimentally affected the livelihood and health of people in China. During the spread of COVID-19, colleagues who have been working at the frontline have had to fa...
Autores principales: | Song, Yueqi, Peng, Wujian, Tang, Donge, Dai, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426163/ https://www.ncbi.nlm.nih.gov/pubmed/32838187 http://dx.doi.org/10.1007/s42399-020-00448-0 |
Ejemplares similares
-
Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis
por: Savarese, Gianluigi, et al.
Publicado: (2020) -
Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
por: Kim, Ju Hwan, et al.
Publicado: (2020) -
The use of cardiac markers in the prediction of COVID-19
por: Moghadam, Mohamad Gholamhosain, et al.
Publicado: (2023) -
COVID‐19, hypertension, and renin‐angiotensin‐aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
por: Tadic, Marijana, et al.
Publicado: (2020) -
Influence of blood pressure control and application of renin‐angiotensin‐aldosterone system inhibitors on the outcomes in COVID‐19 patients with hypertension
por: Chen, Renzheng, et al.
Publicado: (2020)